Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSAS
- Conditions
- Oropharyngeal CancerCancer of Head and NeckPain, PostoperativePostoperative PainSurgeryCarcinoma of Unknown PrimaryAnalgesia
- Interventions
- Drug: PlaceboDrug: Dexamethasone
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 18
- Registration Number
- NCT04189107
- Locations
- 🇩🇰
Department of Otorhinolaryngology, Head and Neck Surgery & Audiology, Copenhagen, Denmark
Dexamethasone and Postoperative Bleeding Following Tonsillectomy in Children
- Conditions
- Pain, PostoperativeTonsillar BleedingPostoperative Nausea and Vomiting
- Interventions
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Walid HABRE
- Target Recruit Count
- 523
- Registration Number
- NCT04188431
- Locations
- 🇨🇦
Queen Elizabeth Hospital of Montreal, Mc Gill, Montreal, Quebec, Canada
🇨🇭geneva Children's Hospital, Geneva, Switzerland
Subjective Intraoperative Use of Epidural Steroid Administration Following Discectomy
- First Posted Date
- 2019-12-02
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- University of Missouri-Columbia
- Target Recruit Count
- 200
- Registration Number
- NCT04182997
- Locations
- 🇺🇸
Missouri Orthopaedic Institute, Columbia, Missouri, United States
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2019-12-02
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 419
- Registration Number
- NCT04181827
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Cancer Center-Scottsdale, Phoenix, Arizona, United States
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
- Conditions
- Multiple MyelomaRefractory Multiple MyelomaMultiple Myeloma in RelapseRelapse
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Andrew Yee, MD
- Target Recruit Count
- 43
- Registration Number
- NCT04176718
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Intracanalicular Dexamethasone Insert for Post-Corneal Cross-Linking Inflammation and Pain- The LINK Study
- Conditions
- Postoperative PainKeratoconus, UnstableCollagen Crosslinking
- Interventions
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Sight Medical Doctors PLLC
- Target Recruit Count
- 20
- Registration Number
- NCT04168112
- Locations
- 🇺🇸
SightMD, Babylon, New York, United States
Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease
- Conditions
- Multiple MyelomaExtramedullary Plasmacytoma
- Interventions
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 41
- Registration Number
- NCT04166565
- Locations
- 🇬🇷
Anticancer Hospital of Thessaloniki, Thessaloníki, Greece
🇮🇹University of Bologna, Bologna, Italy
🇮🇹Univerity of Turin, Torino, Italy
Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 19
- Registration Number
- NCT04163107
- Locations
- 🇳🇴
St. Olavs Hospital, Department of Hematology, Trondheim, Norway
🇳🇴Oslo University Hospital, Department of Hematology, Oslo Myeloma Center, Oslo, Norway
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
- Conditions
- Lymphoma, B-Cell
- Interventions
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 18
- Registration Number
- NCT04161248
- Locations
- 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇨🇦University Health Network, Toronto, Ontario, Canada
🇨🇦The Jewish General Hospital, Montreal, Quebec, Canada
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
- Conditions
- Recurrent Follicular LymphomaGrade 3b Follicular LymphomaRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaNon-Hodgkin's Lymphoma
- Interventions
- Drug: CopanlisibDrug: GemcitabineDrug: CarboplatinDrug: DexamethasoneBiological: RituximabBiological: Pegfilgrastim
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 12
- Registration Number
- NCT04156828
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.